文献速递肝病消化道肿瘤与早癌

血清生物可利用25-羟基维生素D而非总水平与肝细胞癌生存相关

Serum Bioavailable, Rather Than Total, 25-hydroxyvitamin D Levels Are Associated With Hepatocellular Carcinoma Survival.
PubMed 文献 · Hepatology · 2020-04-03

该研究纳入1031例新诊断未治疗的肝细胞癌患者,检测血清总、游离及生物可利用25-羟基维生素D水平,分析其与肝癌特异性生存和总生存的关系。中位随访726天,多因素分析显示生物可利用25-羟基维生素D最高四分位组与最低组相比,肝癌特异性生存HR为0.69(95%CI 0.51-0.93),总生存HR为0.71(95%CI 0.53-0.94),而总或游离25-羟基维生素D与生存无关。

要点

  • 生物可利用25-羟基维生素D较高与肝细胞癌患者更好的生存独立相关。
  • 总或游离25-羟基维生素D水平与肝癌生存无显著关联。
  • 生物可利用25-羟基维生素D可能作为肝细胞癌预后生物标志物。

核心结论

  • 较高的生物可利用25-羟基维生素D而非总水平独立关联肝细胞癌患者改善的生存。

研究设计与样本

  • 研究纳入广东肝癌队列2013年9月至2017年4月期间1031例新诊断、未经治疗的肝细胞癌患者。
  • 采用电化学发光免疫分析法检测血清总25-羟基维生素D,两步酶联免疫吸附法检测游离25-羟基维生素D,并通过经验证方程计算生物可利用25-羟基维生素D。
  • 主要结局为肝癌特异性生存和总生存,采用Cox比例风险模型计算多变量风险比和95%置信区间。

主要发现

  • 中位随访726天,430例患者死亡,其中393例死于肝细胞癌。
  • 生物可利用25-羟基维生素D最高四分位组与最低组相比,肝癌特异性生存的多变量调整HR为0.69(95%CI 0.51-0.93;趋势P=0.014)。
  • 生物可利用25-羟基维生素D最高四分位组与最低组相比,总生存的多变量调整HR为0.71(95%CI 0.53-0.94;趋势P=0.013)。
  • 总或游离25-羟基维生素D水平均与肝癌特异性生存或总生存无显著关联。

临床怎么用

  • 在肝细胞癌患者预后评估中,可考虑检测生物可利用25-羟基维生素D而非总水平。
  • 生物可利用25-羟基维生素D可能作为肝细胞癌生存的潜在预后生物标志物。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND AIMS: Free and bioavailable 25-hydroxyvitamin D (25OHD) are emerging measurements of vitamin D status. It remains unclear whether circulating free or bioavailable 25OHD are relevant to hepatocellular carcinoma (HCC) prognosis. Our aim was to test the hypothesis that bioavailable 25OHD may be a better serum biomarker of vitamin D status than total 25OHD on the association with HCC survival. APPROACH AND RESULTS: We included 1,031 newly diagnosed, previously untreated patients with HCC from the Guangdong Liver Cancer Cohort enrolled between September 2013 and April 2017. Serum total 25OHD levels were measured using an electrochemiluminescence immunoassay. Serum-free 25OHD levels were measured using a two-step enzyme-linked immunosorbent assay. Bioavailable 25OHD levels were calculated from measured free 25OHD and albumin using a previously validated equation. Primary outcomes were liver cancer-specific (LCSS) and overall survival (OS). Cox proportional hazards models were performed to calculate the multivariable hazard ratios (HRs) and 95% confidence intervals (CIs). During a median follow-up of 726 days, 430 patients had deceased, including 393 deaths from HCC. In multivariable analyses, higher bioavailable 25OHD levels were significantly associated with better survival, independent of nonclinical and clinical prognostic factors including serum C-reactive protein, Barcelona Clinic Liver Cancer stage, and cancer treatment. The multivariable-adjusted HRs in the highest versus lowest quartile of bioavailable 25OHD levels were 0.69 (95% CI: 0.51, 0.93; P for trend = 0.014) for LCSS and 0.71 (95% CI: 0.53, 0.94; P for trend = 0.013) for OS. In contrast, neither total nor free 25OHD levels were associated with LCSS or OS. CONCLUSIONS: Higher bioavailable, rather than total, 25OHD levels were independently associated with improved survival in a population-based HCC cohort, suggesting a potential utility of bioavailable 25OHD in HCC prognosis.

来源:Hepatology,查看原文。版权归原作者所有。

引用

  1. Fang AP, Long JA, Zhang YJ, et al. Serum Bioavailable, Rather Than Total, 25-hydroxyvitamin D Levels Are Associated With Hepatocellular Carcinoma Survival. Hepatology. 2020. PMID: 31677282. doi:10.1002/hep.31013

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。